Clean Energy Fuels (CLNE) Surprises Wall Street; Argus Sees Upside In Itron (ITRI)


Shares of Clean Energy Fuels Corp. (Nasdaq:CLNE) surged more than 4% in after-hours trading Thursday as the company delivered beter-than-expected numbers in its quarterly financial results

For the fourth quarter 2015, Clean Energy posted revenue of $119.35 million and non-GAAP net income of $7.69 million, or $0.08 per share, well above the Capital IQ Consensus Estimate of ($0.09) loss per share on revenues of $108.85 million for the period

CLNE stock finished the regular session at $3.45, up $0.42 (or +13.86%), with a total volume of 3,083,138 shares traded during the day, a large increase in activity versus its average volume (3m) of 1,703,520

Clean Energy Fuels, which provides natural gas as an alternative fuel for transportation in North America, has 90.57M Shares Outstanding, Market Capitalization (intraday) of $312.48M and CLNE stock 52-week range is from $2.15 to $10.48 per share



Investment analysts at Argus upgraded shares of Itron, Inc. (Nasdaq:ITRI) from a Hold to a Buy rating with a price target of $48.00

Itron recently reported fourth quarter 2015 revenue of $490 million and non-GAAP diluted earnings per share of $0.76 for the period. The company expects to deliver revenues in a range of $1.85 to $1.95 billion for the full year 2016.

The price of ITRI stock surged to touch a new 52-week high of $41.32 in intraday trading, finally closing at $41.32, up $0.82 (or +2.02%) on Thursday’s market activity

Itron, which provides metering solutions to electricity, gas, and water utility markets worldwide, has 37.90M Shares Outstanding, Market Capitalization (intraday) of $1.57B


Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. GalaxyStocks is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at